Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol

Transplant Proc. 2003 Mar;35(2):653-4. doi: 10.1016/s0041-1345(03)00024-1.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antilymphocyte Serum / therapeutic use
  • Basiliximab
  • Drug Therapy, Combination
  • Graft Rejection / epidemiology*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology*
  • Living Donors*
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use*
  • Recombinant Fusion Proteins*
  • Retrospective Studies
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab
  • Mycophenolic Acid
  • Tacrolimus